List view / Grid view
Filter the results
Pfizer has volountarily recalled the migraine medication Relpax because of the potential presence of Pseudomonas and Burkholderia.
Rising temperatures will likely accelerate the spread of vector-borne diseases, resulting in an increased demand for vaccines. European Pharmaceutical Review investigates a Morgan Stanley report on the pharmaceutical beneficiaries of climate change.
The US Federal Trade Commission is investigating whether Johnson and Johnson violated antitrust laws with its medication, Remicade.
The global controlled release drug delivery market will be worth an estimated $91.2 billion by 2026, according to a new study.
Vizimpro (dacomitinib) has been recommended as a first-line treatment option for patients with lung cancer.
The price of over 3400 drugs have been hiked in the first half of 2019, surpassing the number of hikes imposed during the same period last year.
Substandard and counterfeit drugs can negatively impact the pharmaceutical industry and patients. Here, we investigate counterfeits in south-east Asia and possible solutions.
Pharmaceutical company, Pfizer, has announced it has completed the acquisition of Therachon for $340 million.
Former FDA Commissioner, Scott Gottlieb, who stepped down from the administration in April, has joined Pfizer’s board of directors.
According to Reuters, GSK has started the sale of some consumer health brands as it seeks to raise £1 billion.